What is Curza?
Cūrza is dedicated to pioneering new classes of antibiotics, with a primary focus on addressing drug-resistant Gram-negative bacteria and the challenging ESKAPE pathogens. The company has engineered proprietary compounds that demonstrate potent efficacy against a spectrum of infectious diseases, including those complicated by biofilms. This strategic focus positions Curza at the forefront of innovation in a critical area of public health.
How much funding has Curza raised?
Curza has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for Curza?
With its substantial late-stage funding, Curza is poised for significant expansion and advancement of its lead program, CZ-02. The company's trajectory suggests a move towards late-stage clinical development and potential commercialization. This investment will likely accelerate the validation of their proprietary drug designs and their impact on treating difficult-to-treat infections, reinforcing their commitment to tackling global health challenges through scientific advancement.
See full Curza company page
